Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELIOS: OTX-TKI in NPDR
NCT05695417Phase 1Active, not recruiting
- Sponsor
- Ocular Therapeutix
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of axitinib (2 arms), sponsored by Ocular Therapeutix. Primary endpoint: Safety and Tolerability (Frequency of treatment emergent adverse events) at 52 weeks. Started Jan 2023; status: active, not recruiting.
02
Drugs
axitinib
Beyond the preview
Go deeper on NCT05695417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05695417.